Abbott Beats on EPS, Affirms View Zacks.com Abbott Labs, along with partner Biogen (BIIB - Analyst Report), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on levodopa-carbidopa intestinal gel (LCIG ... |
